Financial Performance - The company's operating revenue for 2023 reached ¥1,905,182,163.02, representing a 25.75% increase compared to ¥1,515,046,453.62 in 2022[24] - Net profit attributable to shareholders of the listed company was ¥106,497,782.30, up 24.29% from ¥85,681,971.00 in the previous year[24] - The net profit after deducting non-recurring gains and losses was ¥81,806,805.66, reflecting a 20.21% increase from ¥68,053,308.12 in 2022[24] - The company's cash flow from operating activities was ¥28,252,316.37, a significant decrease of 88.16% compared to ¥238,711,442.29 in 2022[24] - The net assets attributable to shareholders of the listed company increased by 10.50% to ¥1,120,385,678.79 from ¥1,013,887,896.49 at the end of 2022[24] - The basic earnings per share increased to 0.27 yuan, reflecting a growth of 28.57% year-on-year[26] - The weighted average return on equity rose to 9.98%, an increase of 1.16 percentage points from the previous year[26] - The gross profit margin decreased by 5.08 percentage points to 52.77% due to a 40.91% increase in operating costs[86] Dividend and Shareholder Returns - The proposed cash dividend for 2023 is ¥1.25 per 10 shares, totaling ¥50,013,594 (including tax), which accounts for 46.96% of the net profit attributable to shareholders[6] - The company does not plan to issue new shares or increase capital reserves this year[6] - The profit distribution plan is subject to approval at the company's 2023 annual general meeting[200] Research and Development - The company has 128 products under research, with approximately 50% focused on pediatric applications, particularly in respiratory and digestive systems[36] - The company actively invests in R&D, with established research centers and collaborations to enhance innovation capabilities[53] - The company is committed to enhancing its R&D capabilities in pediatric and traditional Chinese medicine through various collaboration and innovation strategies[57] - Total R&D investment reached 147.77 million RMB, accounting for 7.76% of operating revenue[100] - The company is increasing its R&D investments, focusing on multiple formulation developments and consistency evaluation projects, which may impact its financial performance[163] Product Development and Market Strategy - The company launched three new products during the reporting period, enhancing its product portfolio and supporting sustainable development[72] - The company is focusing on expanding its marketing network to include new retail channels, adapting to national healthcare policies[80] - The company has established a marketing strategy focused on "market-oriented and consumer-centered" approaches, targeting medical institutions and retail pharmacies while expanding e-commerce channels[69] - The company is positioned to deepen its involvement in the pediatric medicine market, particularly in R&D, to better serve children's health needs[56] Quality Control and Compliance - The company achieved a 100% product pass rate, ensuring strict quality control and adherence to production standards[38] - The company has established a robust quality management system, including ICH Q10 and ISO9001 certifications, ensuring high standards in drug production and quality control[75] - The company has strengthened its governance and risk management systems, ensuring compliance and enhancing organizational effectiveness[40] Market Trends and Industry Insights - In 2023, the pharmaceutical manufacturing industry in China generated revenue of CNY 25,205.7 billion, with stable market demand and sales growth outpacing overall levels[47] - The government has introduced policies to support pediatric drug development, creating a favorable environment for growth in the pediatric drug market[51] - The company acknowledges the risk of intensified market competition in the pediatric medication sector and other therapeutic areas due to increasing market demand and new entrants[164] Corporate Governance and Management - The company has established a dedicated board secretary to manage investor relations and ensure compliance with information disclosure regulations[170] - The board of directors and supervisory board strictly adhere to their responsibilities and obligations as outlined in the company's articles of association[170] - The company has implemented measures to prevent information leakage and ensure fairness in information disclosure[170] Sustainability and Social Responsibility - The company is committed to creating a national-level green factory, focusing on energy conservation and environmental protection, with ongoing investments in sustainable development[43] - The company has been recognized as a "No Waste Pharmaceutical Enterprise" by local authorities, reflecting its commitment to sustainable practices[43] - The management team emphasizes a commitment to sustainability and corporate social responsibility in future business strategies[176] Employee and Talent Management - The company emphasizes talent development through a comprehensive training system, including new employee orientation and specialized skills training for various roles[198] - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 6.9185 million RMB[183] - The company has established a performance assessment system to create a competitive salary structure, linking employee compensation closely with job responsibilities and performance[197] Future Outlook and Strategic Initiatives - The company plans to expand its market presence and is exploring potential mergers and acquisitions to enhance its competitive edge[176] - The company aims to improve patient outcomes through innovative therapies and expanded access to medications[127] - The company anticipates continued growth in the pharmaceutical sector, supported by ongoing research and development initiatives[110]

证券代码：605199 证券简称：葫芦娃 公告编号：2024-022 海南葫芦娃药业集团股份有限公司 关于续聘 2024 年度财务审计机构和 内部控制审计机构的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 安永华明及从业人员近三年没有因执业行为受到任何刑事处罚、行政处罚，以及行 业协会等自律组织的自律监管措施和纪律处分。曾收到证券监督管理机构出具警示函一 次，涉及两名从业人员。前述出具警示函的决定属监督管理措施，并非行政处罚。曾收 到深圳证券交易所对本所的两名从业人员出具书面警示的自律监管措施一次，亦不涉及 处罚。根据相关法律法规的规定，前述监管措施不影响安永华明继续承接或执行证券服 务业务和其他业务。 拟聘任的会计师事务所名称：安永华明会计师事务所(特殊普通合伙) 一、拟聘任会计师事务所的基本情况 （一）机构信息 1.基本信息 安永华明会计师事务所（特殊普通合伙）以下简称"安永华明"，于 1992 年 9 月成 立，2012 年 8 月完成本土化转制，从一家中外合作的有限责任制事务所转制为特殊普通 合 ...

证券代码：605199 证券简称：葫芦娃 公告编号：2024-027 海南葫芦娃药业集团股份有限公司 关于召开 2023 年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东大会类型和届次 2023 年年度股东大会 股东大会召开日期：2024年5月22日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 (四) 现场会议召开的日期、时间和地点 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2024 年 5 月 22 日 至 2024 年 5 月 22 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 (六) ...

Financial Performance - The company's operating revenue for Q1 2024 was CNY 430,405,183.89, representing a decrease of 18.37% compared to the same period last year[5]. - The net profit attributable to shareholders for Q1 2024 was CNY 29,032,483.80, down 28.42% year-on-year[5]. - The basic earnings per share for Q1 2024 was CNY 0.07, reflecting a decline of 30.00% compared to the previous year[5]. - Total operating revenue for Q1 2024 was CNY 430.41 million, a decrease of 18.4% compared to CNY 527.26 million in Q1 2023[17]. - Net profit for Q1 2024 was CNY 30.16 million, a decline of 25.4% from CNY 40.42 million in Q1 2023[19]. - Earnings per share for Q1 2024 were CNY 0.07, compared to CNY 0.10 in Q1 2023[20]. Cash Flow - The net cash flow from operating activities for Q1 2024 was CNY -190,443,500.39, indicating a significant cash outflow[5]. - Cash flow from operating activities in Q1 2024 was negative CNY 190.44 million, worsening from negative CNY 118.33 million in Q1 2023[24]. - Cash outflow from operating activities totaled CNY 496.73 million in Q1 2024, compared to CNY 482.50 million in Q1 2023[24]. - Investment activities generated a net cash outflow of CNY 91.93 million in Q1 2024, compared to CNY 123.10 million in Q1 2023[24]. - Cash inflow from financing activities in Q1 2024 was CNY 98.98 million, significantly lower than CNY 257.35 million in Q1 2023[24]. - The company reported a significant increase in financial expenses, with interest expenses rising to CNY 5.88 million in Q1 2024 from CNY 3.81 million in Q1 2023[17]. - In Q1 2024, the company reported a net cash flow from financing activities of -$1,692,343.71, a significant decrease compared to $100,205,850.47 in Q1 2023[25]. - The total cash and cash equivalents at the end of Q1 2024 were $236,868,072.80, down from $322,610,823.41 in Q1 2023, reflecting a decrease of approximately 26.5%[25]. - The cash outflow from financing activities totaled $100,672,343.71 in Q1 2024, compared to $157,139,915.35 in the same period last year, indicating a reduction of about 36%[25]. - The company experienced a net decrease in cash and cash equivalents of $284,069,641.62 in Q1 2024, compared to a decrease of $141,230,543.14 in Q1 2023[25]. - The beginning cash and cash equivalents balance for Q1 2024 was $520,937,714.42, which is an increase from $463,841,366.55 in Q1 2023[25]. Assets and Liabilities - The total assets at the end of Q1 2024 were CNY 3,028,414,701.53, a decrease of 1.05% from the end of the previous year[6]. - As of March 31, 2024, the company's total assets amounted to RMB 3,028,414,701.53, a decrease from RMB 3,060,548,675.78 as of December 31, 2023, reflecting a decline of approximately 1.06%[14]. - The company's cash and cash equivalents decreased to RMB 251,166,833.49 from RMB 522,689,865.24, representing a significant decline of about 52.0%[14]. - Current liabilities totaled RMB 1,214,446,409.49, up from RMB 1,082,500,727.83, reflecting an increase of approximately 12.2%[16]. - The company's long-term borrowings decreased to RMB 543,678,654.80 from RMB 737,428,654.80, a reduction of about 26.3%[16]. - The total liabilities decreased to RMB 1,838,677,753.43 from RMB 1,901,175,403.43, indicating a decline of approximately 3.3%[16]. - The retained earnings increased to RMB 394,131,600.27 from RMB 365,099,116.47, reflecting a growth of about 7.1%[16]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 32,421[11]. - The largest shareholder, Hainan Huluwa Investment Development Co., Ltd., held 41.76% of the shares, totaling 167,079,000 shares[11]. Other Financial Metrics - The weighted average return on equity for Q1 2024 was 2.56%, a decrease of 1.36 percentage points year-on-year[5]. - The company reported a government subsidy of CNY 6,328,051.96, which is included in non-operating income[7]. - Accounts receivable increased to RMB 557,741,207.29 from RMB 540,600,831.70, showing a growth of approximately 3.2%[14]. - Inventory rose to RMB 306,845,689.51 from RMB 265,561,874.47, indicating an increase of around 15.5%[15]. - The company's long-term equity investments increased to RMB 22,959,989.94 from RMB 20,444,191.34, showing a growth of about 12.3%[15]. - The company reported a significant increase in prepayments, which rose to RMB 73,931,621.66 from RMB 25,522,559.90, marking an increase of approximately 189.5%[14]. - Total operating costs for Q1 2024 were CNY 402.98 million, down 13.7% from CNY 467.07 million in Q1 2023[17].

证券代码：605199 证券简称：葫芦娃 公告编号：2024-021 海南葫芦娃药业集团股份有限公司 关于 2023 年度募集资金存放与使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据上海证券交易所发布的《上海证券交易所股票上市规则》、《上海证券交易 所上市公司自律监管指引第1号——规范运作》、《上市公司监管指引第2号——上市 公司募集资金管理和使用的监管要求》及相关格式指引的有关规定，公司董事会编制 了公司关于2023年度募集资金存放与使用情况的专项报告。具体情况如下： 一、资金募集基本情况 单位：人民币元 1 | 项目 | 金额 | | --- | --- | | 募集资金总额 | 208,119,000.00 | | 减：承销佣金及其他发行费用 | 57,079,347.77 | | 募集资金净额 | 151,039,652.23 | | 减：以募集资金置换预先投入自筹资金的金额（注1） | 13,914,870.00 | | 减：募集资金直接投入募投项目金额 | 41,889,688.17 | ...

证券代码：605199 证券简称：葫芦娃 公告编号：2024-026 二、监事会会议审议情况 （一）审议通过《关于公司 2023 年度监事会工作报告的议案》 表决结果：3 票同意，0 票反对，0 票弃权。 海南葫芦娃药业集团股份有限公司 第三届监事会第三次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、 监事会会议召开情况 （一）海南葫芦娃药业集团股份有限公司（以下简称"公司"）第 三届监事会第三次会议的召开符合《公司法》《公司章程》和《监事 会议事规则》的有关规定，会议合法有效。 （二）会议通知和材料于 2024 年 4 月 16 日以邮件方式发出。 （三）会议于 2024 年 4 月 26 日在海南省海口市国家高新区药谷工 业园二期药谷四路 8 号会议室现场召开。 （四）公司监事会会议应出席监事 3 人，实际出席监事 3 人。 （五）本次会议由监事会主席徐鹏先生主持召开，董事会秘书王清 涛先生、证券事务代表王海燕女士列席会议。 本议案尚须提交公司 2023 年年度股东大会审议。 （二）审议通过《关于公司 ...

海南葫芦娃药业集团股份有限公司 内部控制审计报告 2023年12月31日 内部控制审计报告 安永华明（2024）专字第70060529_X01号 海南葫芦娃药业集团股份有限公司 海南葫芦娃药业集团股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我们审 计了海南葫芦娃药业集团股份有限公司2023年12月31日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企业内部控制 评价指引》的规定，建立健全和有效实施内部控制，并评价其有效性是海南葫芦娃药 业集团股份有限公司董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表审计 意见，并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于情况 的变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低，根据内 部控制审计结果推测未来内部控制的有效性具有一定风险。 四、财务报告内部控制审计意见 我们认为，海南葫芦娃药业集团 ...

关于海南葫芦娃药业集团股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 目 录 1、 专项审计报告 2、 附表 委托单位：海南葫芦娃药业集团股份有限公司 审计单位：安永华明会计师事务所（特殊普通合伙） 联系电话：0531-55807088 关于海南葫芦娃药业集团股份有限公司 非经营性资金占用及其他关联资金往来情况的专项说明 2023 年度 1 您可使用手机"扫"成址入"注册会计师行业统一监管平台（bttp://www.gov.co) "儿" 您可使用手机"扫一点"成进入"注册会计师行业统一监管平台（bttp://www.gov.co）"进一步 " Ernst & Young Hua Ming LLP Level 17, Ernst & Young Tower Oriental Plaza, 1 East Chang An Avenue Dongcheng District Beijing, China 100738 安永华明会计师事务所（特殊普通合伙） 中国北京市东城区东长安街１号 东方广场安永大楼 17 层 邮政编码:100738 Tel 电话: +86 10 5815 3000 ...

关于公司及子公司向金融机构申请2024年度综合授信额度 证券代码：605199 证券简称：葫芦娃 公告编号：2024-024 海南葫芦娃药业集团股份有限公司 及提供相应担保额度预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示: 1 被担保人名称及是否为上市公司关联人：海南葫芦娃药业集团股份有限公司（以 下简称"葫芦娃股份"或"公司"）合并报表范围内的子公司广西维威制药有限公司（以 下简称"广西维威"）、来宾市维威药物提取有限公司（以下简称"来宾维威"）、海南 葫芦娃药业有限公司（以下简称"海南葫芦娃"）、浙江葫芦世家药业有限公司（以下 简称"浙江葫芦世家"）、海南葫芦娃科技开发有限公司（以下简称"葫芦娃科技"）海 南葫芦娃医疗保健生物科技有限公司（以下简称"葫芦娃医疗保健"）、江西荣兴药业 有限公司（以下简称"江西荣兴"），非上市公司关联方。 本次担保金额及已实际为其提供的担保余额：公司及合并报表范围内的子公司 拟向银行等金融机构或其他机构新增申请总计不超过 15 亿元的贷款融资额度（具 体贷款融 ...

海南葫芦娃药业集团股份有限公司 募集资金存放与实际使用情况鉴证报告 2023年度 海南葫芦娃药业集团股份有限公司 目 录 | | 页 次 | | --- | --- | | 一、募集资金存放与实际使用情况鉴证报告 | 1 - 2 | | 二、海南葫芦娃药业集团股份有限公司 | | | 2023年度募集资金存放与实际使用情况的专项报告 | 3 - 7 | 我们接受委托，对后附的海南葫芦娃药业集团股份有限公司2023年度募集资金存 放与实际使用情况的专项报告（"募集资金专项报告"）进行了鉴证。按照《上市公 司监管指引第2号——上市公司募集资金管理和使用的监管要求》、《上海证券交易所 上市公司自律监管指引第1号——规范运作》及相关格式指南编制募集资金专项报告， 并保证其内容真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏是海南葫 芦娃药业集团股份有限公司董事会的责任。我们的责任是在执行鉴证工作的基础上对 募集资金专项报告独立发表鉴证意见。 我们按照《中国注册会计师其他鉴证业务准则第3101号——历史财务信息审计或 审阅以外的鉴证业务》的规定执行了鉴证业务。该准则要求我们计划和执行鉴证工 作，以对募集资金专项报 ...